The dementia-seizure evidence gap runs through all of it.
Subclinical seizure activity in Alzheimer's patients precedes cognitive deterioration, confounds behavioral endpoints, and contributes to patient heterogeneity that complicates trial interpretation. The peer-reviewed literature on this overlap is growing. Organizing it through a clinical framework purpose-built for this population is what CRISP does.
The Clinical Context
Epileptiform activity in late-onset Alzheimer's disease is more prevalent than previously recognized and is routinely missed in clinical settings. Standard observation and short-duration EEG are insufficiently sensitive to detect it. The peer-reviewed literature is now explicit on this point.
For organizations developing therapeutics in this space, that gap creates specific and recurring challenges: behavioral endpoints that may reflect ictal activity rather than treatment response, patient populations with uncharacterized seizure risk, and safety signals that require clinical context the standard literature search doesn't efficiently provide.
The Dementia Seizure Spectrum™ Framework provides the clinical taxonomy that connects these concerns — organizing what the literature establishes across four observable domains that map directly to what appears in trial data, patient assessments, and adverse event reports.
Nature Reviews Neurology · 2024 · Kamondi et al.
"Detection of epileptiform activity in Alzheimer's disease has substantial clinical importance and remains underaddressed" — subclinical epileptiform activity precedes cognitive deterioration and is routinely missed by standard observation and short-duration EEG.
PMID: 38356056 · Nature Reviews Neurology, 2024
Patient selection and population heterogeneity
Uncharacterized seizure risk in trial populations introduces heterogeneity that complicates endpoint interpretation and responder analysis. The literature on seizure prevalence by dementia subtype, disease stage, and comorbidity profile is now substantial enough to inform exclusion criteria and stratification design.
Behavioral endpoint validity
Behavioral assessment tools used as primary or secondary endpoints — NPI, ADAS-Cog, ADCS-ADL — capture signals that overlap with ictal and peri-ictal behavioral presentations. A patient with unrecognized subclinical seizure activity may appear to be a non-responder when the confound is neurological, not pharmacological.
Safety signal interpretation
Adverse event reports describing sudden behavioral changes, unexplained agitation, or episodic confusion in dementia trial participants may reflect seizure-consistent activity rather than drug effect. Interpreting these signals accurately requires clinical context the standard literature search doesn't organize efficiently.
Regulatory evidence context
Clinical arguments about seizure activity in dementia populations require organized, scored evidence — not keyword searches. The methodology behind the evidence evaluation is as important as the evidence itself in regulatory submissions and scientific review.
The Interpretation Problem
When the dementia-seizure overlap is unaccounted for in trial design, behavioral observations generate ambiguous signals. The DSS Framework makes the alternative interpretation visible — and lets trial teams decide whether it requires action.
What CRISP Delivers for Life Sciences
Every CRISP brief commissioned through the life sciences context is organized through the Dementia Seizure Spectrum™ Framework and evaluated using Modified Cochrane GRADE methodology — scoring each paper for evidence quality, bias risk, and clinical relevance with a disclosed, reproducible formula.
What the evidence establishes about seizure prevalence by dementia subtype, disease stage, and comorbidity profile — organized by DSS domain rather than keyword, scored for evidence quality, with explicit gap analysis on where the literature is thin.
Example questions
Mapping behavioral signals that may reflect ictal activity to clinical assessment frameworks — so endpoints are designed with awareness of the dementia-seizure overlap from the start, and behavioral deterioration can be distinguished from neurological confounding where the evidence supports that distinction.
Example questions
Structured evidence on seizure-consistent behavioral changes that may appear in adverse event data — with explicit gap analysis identifying where the literature is thin, contested, or absent. Organized by DSS domain so safety signals can be evaluated against the published clinical taxonomy for this population.
Example questions
Clinical intelligence organized through a documented framework — the Dementia Seizure Spectrum™ — with transparent evidence evaluation using Modified Cochrane GRADE methodology. Every score disclosed, every dimension visible, formula available for review. Supporting clinical arguments about seizure activity in dementia populations where methodology transparency matters.
Example questions
The Pipeline Context
The Alzheimer's therapeutics pipeline had 138 drugs across 182 active clinical trials in 2024, with the 2025 pipeline larger still. NIH Alzheimer's disease research funding runs at $3.8 billion per year. Single Alzheimer's assets are being acquired at valuations exceeding $1 billion.
Across this pipeline, the dementia-seizure overlap appears in patient selection, endpoint validity, safety monitoring, and regulatory submissions. It is not a niche concern for a subset of trials — it is a recurring clinical variable that the evidence base is increasingly explicit about, and that trial design has not yet fully integrated.
CRISP provides structured intelligence on this overlap — not a general literature search, but a domain-specific evidence synthesis organized through the only clinical taxonomy purpose-built for seizure presentation in dementia populations.
Drugs in 182 active Alzheimer's trials (2024)
PMC / Alzheimer's Association
Alzheimer's therapeutics market, projected $16.43B by 2033
Coherent Market Insights
NIH Alzheimer's research funding per year
Alzheimer's Impact Movement / Congress, 2024
AbbVie acquisition of Aliada Therapeutics — single asset
Clinical Trials Arena, October 2024
What CRISP Is — and Isn't
Pharmaceutical and life sciences organizations have internal medical affairs and clinical development teams with established literature review processes. CRISP is not positioned as a replacement for those resources.
What CRISP provides that internal generalist review does not: a purpose-built clinical taxonomy (the DSS Framework) for seizure presentation in dementia populations, real-time PubMed retrieval scored by Modified Cochrane GRADE methodology, and a structured gap analysis identifying where the literature is genuinely thin — organized in the format that clinical development teams and medical affairs functions can use directly.
The dementia-seizure overlap sits at the intersection of neurology and geriatrics. General literature review finds papers. CRISP finds the right papers, scores them, and maps them to the clinical framework your team will actually use.
Research Intelligence Consultation
Trial design, endpoint development, safety signal context, or regulatory evidence support. Modified Cochrane GRADE methodology. DSS Framework organized. 2–3 business days from confirmation.